Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerold Bepler

Showing results (51-60 of 156) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinomaValsamo K Anagnostou, Konstantinos N Syrigos, Gerold Bepler, et al.
Chest|November 24, 2005
Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancerNithya Ramnath, Eric Sommers, Lary Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancerGerold Bepler, Irina Kusmartseva, Swati Sharma, et al.
Plos One|March 14, 2013
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacyJun Zhou, Zhengming Chen, Agnes Malysa, et al.
Cancer Biology & Therapy|July 28, 2009
Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cellsJingchun Gao, Zhong Zheng, Bhupendra Rawal, et al.
Journal of Cellular Physiology|June 29, 2018
RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancerMay Chammaa, Agnes Malysa, Carlos Redondo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancerYun Oh, Roy S Herbst, Howard Burris, et al.
BJU International|May 5, 2010
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patientsLauren C Harshman, Gerold Bepler, Zhong Zheng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2010
Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancersTawee Tanvetyanon, Lary Robinson, K Eric Sommers, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 6, 2010
Parameters for individualizing systemic therapy in non-small cell lung cancerShirish M Gadgeel, Michele L Cote, Ann G Schwartz, et al.
Pageof 16

Showing results (51-60 of 156) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinomaValsamo K Anagnostou, Konstantinos N Syrigos, Gerold Bepler, et al.
Chest|November 24, 2005
Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancerNithya Ramnath, Eric Sommers, Lary Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancerGerold Bepler, Irina Kusmartseva, Swati Sharma, et al.
Plos One|March 14, 2013
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacyJun Zhou, Zhengming Chen, Agnes Malysa, et al.
Cancer Biology & Therapy|July 28, 2009
Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cellsJingchun Gao, Zhong Zheng, Bhupendra Rawal, et al.
Journal of Cellular Physiology|June 29, 2018
RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancerMay Chammaa, Agnes Malysa, Carlos Redondo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancerYun Oh, Roy S Herbst, Howard Burris, et al.
BJU International|May 5, 2010
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patientsLauren C Harshman, Gerold Bepler, Zhong Zheng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2010
Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancersTawee Tanvetyanon, Lary Robinson, K Eric Sommers, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 6, 2010
Parameters for individualizing systemic therapy in non-small cell lung cancerShirish M Gadgeel, Michele L Cote, Ann G Schwartz, et al.
Pageof 16